Abstracts Archive - Page 2216 of 2425 - ACR Meeting Abstracts

Abstract Number: 518 • 2013 ACR/ARHP Annual Meeting
Vitamin D In Sjogren’s Syndrome
Suneet Grewal¹, Judith A. James², R. Hal Scofield³, Kathy L. Sivils⁴, Michael H. Weisman⁵ and Swamy Venuturupalli⁶, ¹Division of Rheumatology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁶Cedars-Sinai Medical Center, West Hollywood, CA
Background/Purpose: Unlike other autoimmune diseases in which an association with vitamin D deficiency has been established, the role of vitamin D in Sjogren’s syndrome has…
Abstract Number: 519 • 2013 ACR/ARHP Annual Meeting
Identification Of IgG4-Related Disease and Analysis Of IgG4 Serum Levels In Different Subgroups Of Patients With Sjögren’s Syndrome
Antónia Szántó¹, Gábor Nagy², Csaba Molnár³ and Margit Zeher¹, ¹Clinical Immunology, University of Debrecen, Medical and Health Science Center, Institute for Medicine, Debrecen, Hungary, ²Regional Immunological Laboratory, University of Debrecen, Medical and Health Science Center, Institute for Medicine, Debrecen, Hungary, ³University of Debrecen, Medical and Health Science Center, Institute for Pathology, Debrecen, Hungary
Background/Purpose: In the clinical diagnostic criteria of IgG4-related disease (IgG4-RD), Sjögren’s syndrome (SS) appears as one of the exclusion criteria. However, in Europe, where Mikulicz’s…
Abstract Number: 520 • 2013 ACR/ARHP Annual Meeting
Chronic Obstructive Pulmonary Disease Is Very Common in Primary Sjögren’s Syndrome
Anna M. Nilsson¹, Elke Theander², Roger Hesselstrand³, Eeva Piitulainen⁴, Sandra Diaz⁵, Olle Ekberg⁵, Per Wollmer⁶ and Thomas Mandl⁷, ¹Dept of Rheumatology, Skane University Hospital Malmo, Lund University, Malmo, Sweden, ²Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ³Rheumatology, Lund University, Lund, Sweden, ⁴Dept of Lung medicine, Lund University & Skåne University Hospital, Malmö, Sweden, ⁵Dept of Radiology, Skåne University Hospital Malmo, Lund University, Malmö, Sweden, ⁶Dept of Clinical Physiology, Skane University Hospital Malmo, Lund University, Malmö, Sweden, ⁷Dept of Rheumatology, Skåne University Hospital Malmo, Lund University, Sweden, Malmö, Sweden
Background/Purpose: To study the prevalence of chronic obstructive pulmonary disease (COPD) in patients with primary Sjögren's syndrome (pSS) and its association with respiratory symptoms, pulmonary…
Abstract Number: 498 • 2013 ACR/ARHP Annual Meeting
A Systematic Review and Meta-Analysis Comparing Low- Versus High-Dose Rituximab For Rheumatoid Arthritis
Markus Bredemeier, Fernando K. de Oliveira and Claúdia M. Rocha, Rheumatology, Hospital Nossa Senhora da Conceição - Grupo Hospitalar Conceição, Porto Alegre, Brazil
Background/Purpose: The approved dose of rituximab (RTX) for rheumatoid arthritis (RA) is 2x1000 mg infusions given 2 weeks apart. There is contradictory evidence regarding the…
Abstract Number: 480 • 2013 ACR/ARHP Annual Meeting
Levels Of Circulating Mirnas Before and After 12 Months Therapy With Dmards In Patients With Early Rheumatoid Arthritis
Mária Filková¹, Borbala Aradi², Ladislav Senolt³, Klara Prajzlerova⁴, Serena Vettori², Herman F. Mann⁵, Jiri Vencovsky⁴, K. Pavelka⁶, Beat A. Michel⁷, Renate E Gay², Steffen Gay² and Astrid Jüngel², ¹Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ²Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Zurich, Switzerland, ³Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁴Institute of Rheumatology, Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁵Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, ⁶Department of Clinical and Experimental Rheumatology, Charles University, Prague, Czech Republic, ⁷Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: The altered expression of cellular miRNAs in the immune and resident cells involved in the pathogenesis of rheumatoid arthritis (RA) has been shown to…
Abstract Number: 481 • 2013 ACR/ARHP Annual Meeting
Down-Titration of Biological Therapies In Rheumatoid Arthritis In Daily Clinical Practice
Miguel Arredondo¹, Iciar Cañamares², Esther Ramírez-Herráiz², Isidoro Gonzalez-Alvaro³, Alberto Garcia-Vadillo³, Alberto Morell¹, Rosario Garcia-Vicuña⁴ and Jose María Alvaro-Gracia⁵, ¹Unidad de Terapias Biológicas, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ²Servicio de Farmacia, Hospital Universitario de La Princesa, Madrid, Spain, ³Servicio de Reumatología, Hospital Universitario de La Princesa, Madrid, Spain, ⁴Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ⁵Unidad de Terapias Biológicas. Servicio de Reumatología, Hospital Universitario de La Princesa, Madrid, Spain
Background/Purpose: One of the limiting factors for the use of biological therapies (BT) is cost. For this reason, the development of cost optimization strategies without…
Abstract Number: 482 • 2013 ACR/ARHP Annual Meeting
Methotrexate Use At Infliximab Initiation and Impact On Treatment Outcomes: An Analysis From A Canadian Registry
Denis Choquette¹, J. Carter Thorne², John T. Kelsall³, Michel Zummer⁴, Michael Starr⁵, Maqbool K. Sheriff⁶, William G. Bensen⁷, Andrew Chow⁸, Philip Baer⁹, Emmanouil Rampakakis¹⁰, John S. Sampalis¹⁰, Francois Nantel¹¹, Allen J. Lehman¹², Susan M. Otawa¹² and May Shawi¹³, ¹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ²Southlake Regional Health Centre, Newmarket, ON, Canada, ³Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁴Rheumatology, Ch Maisonneuve-Rosemont, Montreal, QC, Canada, ⁵Montreal General Hospital, Montreal, QC, Canada, ⁶Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁷Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ⁸University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, ⁹Private Practice, Scarborough, ON, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹Janssen Inc., Toronto, ON, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹³Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada
Background/Purpose: Clinical trials of anti-TNF therapies have shown that concurrent methotrexate (MTX) therapy enhances the efficacy of infliximab (IFX)1. Data on the benefits of combination…
Abstract Number: 483 • 2013 ACR/ARHP Annual Meeting
Adalimumab and Methotrexate Pharmacokinetics Following Combination Therapy With Different Methotrexate Doses in Methotrexate and Biologic-Naïve Rheumatoid Arthritis Patients: Concerto Study
Sandra L Goss¹, Cheri E Klein¹, Hartmut Kupper², Gerd Burmester³ and Walid Awni¹, ¹AbbVie Inc., North Chicago, IL, ²AbbVie Deutschland GmBH & Co. KG, Ludwigshafen, Germany, ³Department of Rheumatology & Clinical Immunology, Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany
Background/Purpose: Higher exposure and lower immunogenicity rates have been observed for adalimumab when co-administered with methotrexate (MTX) compared to adalimumab monotherapy. The CONCERTO study was…
Abstract Number: 484 • 2013 ACR/ARHP Annual Meeting
Response To Biologic Disease-Modifying Anti-Rheumatic Drugs After Discontinuation Of Anti-Tumor Necrosis Factor Alpha Agents In Rheumatoid Arthritis Patients
Eric Elkin¹, Max I. Hamburger², Tripthi Kamath³, Sarika Ogale³, Adam Turpcu³, Jae Oh⁴, Kristin King⁴, Monarch Shah¹ and Martin J. Bergman⁵, ¹ICON Clinical Research, San Francisco, CA, ²Rheumatology Associates, Melville, NY, ³Genentech, South San Francisco, CA, ⁴ICON Late Phase and Outcomes Research, San Francisco, CA, ⁵Taylor Hospital, Ridley Park, PA
Background/Purpose: Rheumatoid arthritis (RA) patients who have failed an anti-TNF agent as their first biologic agent have the option of switching to a second aTNF…
Abstract Number: 486 • 2013 ACR/ARHP Annual Meeting
Safety Of Biologic Therapy In Veterans With Rheumatoid Arthritis and Chronic Hepatitis B Infection
Jeffrey R. Curtis¹, Mary J. Burton², Shuo Yang³, Lang Chen⁴, Ted R. Mikuls⁵, Kevin L. Winthrop⁶ and John Baddley⁷, ¹University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL, ²VA Hospital, Jackson, MS, ³Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁶Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, ⁷Medicine, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Among patients with rheumatoid arthritis and hepatitis B infection, the impact of biologic therapy on hepatotoxicity has received limited study. Methods: Using 1997-2011 national…
Abstract Number: 487 • 2013 ACR/ARHP Annual Meeting
The Cost Savings Associated With a Departmental Etanercept Dose Reduction Pathway For Patients With Rheumatic Diseases and Maintained Low Disease Activity
Richard CJ Campbell¹, Emma Sanders¹, Francesca Leone¹, Emma Gilgeours¹, Margaret Sibley¹ and Patrick D. Kiely², ¹Rheumatology, St George's Hospital, London, United Kingdom, ²Rheumatology Dept, St George's Hospital, London, United Kingdom
Background/Purpose: Clinical trials have previously demonstrated that it is safe and effective for some rheumatoid arthritis (RA) patients with low disease activity on full dose…
Abstract Number: 488 • 2013 ACR/ARHP Annual Meeting
The Effect Of Methotrexate On Adalimumab Pharmacokinetics: Pooled Analysis Of Adalimumab Pharmacokinetics In Patients With Rheumatoid Arthritis After Subcutaneous Administration
Walid Awni¹, Sabine Pilari², Ghada Ahmed³ and Peter Noertersheuser², ¹AbbVie Inc., North Chicago, IL, ²AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany, ³AbbVie, North Chicago, IL
Background/Purpose: Co-administration of methotrexate (MTX) has a significant effect on the pharmacokinetics (PK) of adalimumab (ADAL). MTX may impact the PK of other drugs by…
Abstract Number: 489 • 2013 ACR/ARHP Annual Meeting
Combining Methotrexate To Etanercept Does Not Improve Its Retention Rate In Rheumatoid Arthritis Patients When Compared To Etanercept Monotherapy. A Report From The Rhumadata® Clinical Data Base and Registry
Denis Choquette¹, Louis Bessette², Boulos Haraoui¹, Diane Sauvageau³, Jean Pierre Pelletier¹, Jean-Pierre Raynauld³, Edith Villeneuve³ and Louis Coupal¹, ¹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ²Centre Hospitalier Universitaire de Québec, pavillon CHUL, Sainte-Foy, QC, Canada, ³Rheumatology, Institut de Rhumatologie de Montréal, Montreal, QC, Canada
Background/Purpose: Etanercept (ETA) has demonstrated good retention in both mono and combination therapy in clinical trials of rheumatoid arthritis patients followed over short observation periods…
Abstract Number: 490 • 2013 ACR/ARHP Annual Meeting
Does Low Disease Activity At Six Months Predict Remission At 12 Months In Rheumatoid Arthritis Patients Treated With Biologics In a Real–World Setting?
Philip Baer¹, William G. Bensen², Andrew Chow³, Rafat Y. Faraawi^4,5, Denis Choquette⁶, Isabelle Fortin⁷, John T. Kelsall⁸, Dalton E. Sholter⁹, Emmanouil Rampakakis^10,11, John S. Sampalis^10,11, Francois Nantel¹², Allen J. Lehman¹³, May Shawi¹⁴ and Susan M. Otawa¹³, ¹Private Practice, Scarborough, ON, Canada, ²Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ³University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, ⁴Rheumatologist, KW Musculoskeletal Research Inc., Kitchener, ON, Canada, ⁵McMaster University, Hamilton, ON, Canada, ⁶Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ⁷Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada, ⁸Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁹Rheumatology Associates, Edmonton, AB, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹Jewish General Hospital, McGill University, Montreal, QC, Canada, ¹²Janssen Inc., Toronto, ON, Canada, ¹³Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹⁴Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada
Background/Purpose: Remission is considered the treatment goal in the management of patients with rheumatoid arthritis (RA). The objective of this analysis was to determine if…
Abstract Number: 491 • 2013 ACR/ARHP Annual Meeting
Infection Risk Among Patients Receiving Concurrent Denosumab and Biologic Or Non-Biologic DMARD Therapy: An Analysis Of The Consortium Of Rheumatology Researchers Of North America (CORRONA) Registry
Vance J. Bray¹, Adam W. Bagley², Sterling G. West³, Carol J. Etzel⁴, Joel M. Kremer⁵ and Jason R. Kolfenbach⁶, ¹Denver Arthritis Clinic, Denver, CO, ²Internal Medicine, University of Colorado School of Medicine, Aurora, CO, ³Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁴Department of Epidemiology, UT MD Anderson, Houston, TX, ⁵Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, ⁶Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: RANKL is a cytokine member of the tumor necrosis family that mediates osteoclastic bone resorption. Denosumab prevents RANKL from activating RANK on the cell…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].